Raymond James Upgrades Disc Medicine to Strong Buy, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill upgrades Disc Medicine (NASDAQ:IRON) from Outperform to Strong Buy and raises the price target from $50 to $75.
June 09, 2023 | 4:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Disc Medicine (NASDAQ:IRON) has been upgraded to Strong Buy by Raymond James, with a raised price target of $75.
The upgrade from Outperform to Strong Buy by Raymond James, along with the raised price target from $50 to $75, indicates a positive outlook for Disc Medicine's stock. This news is likely to attract more investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100